Anaveon is a late pre-clinical phase biotech based in Basel, Switzerland. It focuses on the development of next generation IL-2 based therapeutic antibodies for tumor immunotherapy in melanoma, kidney carcinoma and lung cancer.
Products, services, technology
ANV419
-
Andreas Katopodis